Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Company Overview

Anthera Pharmaceuticals, Inc. was a biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company’s activities centered on discovering, developing and seeking regulatory approval for prescription medicines, primarily in the areas of gastrointestinal, autoimmune and inflammatory disorders.

Anthera’s lead product candidate was Sollpura, also known as liprotamase, an oral pancreatic enzyme replacement therapy intended for people with exocrine pancreatic insufficiency, including patients with cystic fibrosis and chronic pancreatitis. The company also developed blisibimod, an investigational treatment targeting B-cell activity for autoimmune diseases such as systemic lupus erythematosus, and varespladib, an anti-inflammatory drug candidate evaluated for acute coronary syndrome and other conditions.

Headquartered in San Diego, California, Anthera conducted clinical development activities in the United States and internationally. The company was led for much of its operating history by President and Chief Executive Officer Paul Truex. Anthera later encountered financial difficulties and pursued restructuring and bankruptcy proceedings, making its historical development programs more relevant than its current operating activities.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0010
• Volume: N/A
• Average Volume: 149 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/05/2018
• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ANTH
• CIK: 1316175
• Web: www.anthera.com
• Phone: (410) 350-1839
• Fax: 510-856-5597
• Employees: 20
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.09